Resolute Science

Executive Summary

Resolute Science is a Boston-based private biotechnology company pioneering a novel class of synthetic drug conjugates for the treatment of solid tumors. Founded in 2017, the company aims to address high unmet medical needs in aggressive cancers by leveraging first-in-class small molecule-drug conjugates (SMDCs) designed to selectively deliver cytotoxic payloads to tumor cells. This approach offers potential advantages over traditional antibody-drug conjugates (ADCs), such as improved tumor penetration, reduced immunogenicity, and lower production costs. Resolute Science targets major solid tumor indications, including those resistant to current therapies, with a focus on high-expression tumor antigens. Currently in the pre-clinical stage, Resolute Science has yet to disclose a publicly available pipeline or advance candidates into clinical trials. The company faces typical early-stage risks, including funding requirements, regulatory hurdles, and scientific validation. However, the platform's broad applicability across multiple solid tumor types and its differentiation from established ADC technologies provide a compelling value proposition. Near-term value inflection points may include IND-enabling studies, strategic partnership discussions, and potential series A/B financing to support clinical translation. If successful, Resolute Science could become a key player in the next generation of targeted cancer therapies.

Upcoming Catalysts (preview)

• Q4 2026Lead candidate IND filing60% success
• TBDPreclinical efficacy data presentation at major oncology conference70% success
• H2 2026Series A or B financing round50% success